Targeted antiangiogenic gene therapy is an attractive approach to treat metastatic cancer. However, the relative paucity of the receptors of the commonly used adenovirus serotype 5 in endothelial cells as compared with liver cells undermines the use of this vector for targeting the endothelial cells in tumors. To overcome this problem, we analyzed the ability of a hybrid Ad5/35 virus, where the serotype 5 fiber has been replaced with the fiber from serotype 35, to target tumor vasculature. Infection of human umbilical vein endothelial cells (HUVECs) with Ad5/35 at MOI 120 infected 100% of cells. In contrast, infection with Ad5 at the same MOI infected only 10% HUVECs. Ad5/35 was even more effective in transducing human aortic endothelial cells (HAECs), as infection with Ad5/35 at MOI 3.6 was sufficient to transduce 95% of cells. Gene expression analyses demonstrated that infection of HUVECs and HAECs with Ad5/35 resulted in between 1 and 3 orders of magnitude higher gene expression than infection with Ad5. Furthermore, various liver-derived cells were less infectable with Ad5/35 than Ad5, indicating a favorable toxicity profile for this virus. In a rat colon carcinoma tumor model, Ad5 was located mainly in the liver parenchyma after hepatic artery administration. In contrast, Ad5/35 was found only in the angiogenesis-rich border region of the tumor. Double immunostaining revealed that Ad5/35 colocalized with CD31 and Flk-1 positive endothelial cells. These results indicate that Ad5/ 35 may be useful in anticancer strategies targeting tumor endothelial cells.
Introduction
It is now well recognized that the ability of a tumor to grow and metastasize is dependent on its ability to form new blood vessels, hence providing a rationale for the development of antiangiogenic therapy for cancer. 1 Targeted destruction of the endothelial cell population in tumor vessels is an attractive approach to halt tumor growth, as tumor endothelial cells are genetically stable and easily accessible through the bloodstream. The feasibility of this approach has recently been demonstrated by delivering cytotoxic and antiangiogenic genes specifically to the tumor endothelium using cationic nanoparticles and endothelial progenitorlike cells. 2, 3 Adenovirus is currently the most widely used vector for cancer gene therapy and proof-of-concept using this vector has been demonstrated in numerous preclinical applications. 4, 5 In addition, a level of therapeutic efficacy has been shown in a clinical trial for head and neck cancer. 6 Easy production in high titers, the broad spectrum of infectivity of both resting and proliferating cells along with its highly efficient gene delivery capacity are considered to be advantages of this vector. However, the main limitation undermining the practical use of this vector stems from its mechanism of cell entry. The primary cellular receptor for adenovirus serotype 5, which is currently used in most applications, is the coxsackie-adenovirus receptor (CAR). Adenovirus binds to this receptor via its fiber molecule, thereby allowing it to attach itself to the cell surface. Attached viruses are internalized by a v b 3 and a v b 5 integrins, which function as secondary adenovirus receptors. Although some variation exists between species, CAR is expressed in many normal cell types, including liver, heart, brain, kidney and lung. 7, 8 Limited data exist on the expression of the CAR receptor in endothelial cells in vivo; nevertheless, it has been shown that gene transfer by the standard serotype 5 adenovirus to endothelial cells is inefficient, indicating that this virus has an unfavorable tropism profile for antiangiogenic cancer gene therapy. 9, 10 In addition, Chillon and co-workers have demonstrated that several other adenovirus serotypes also transfer primary endothelial cells poorly in vitro, with the exception of serotypes 3, 17 and 30. However, serotype 35 was not included in this analysis. 11 Several approaches have been used in an attempt to redirect adenoviral tropism away from CAR. The CAR binding site in the fiber protein has been masked by bispecific antibodies directed against the fiber and a receptor expressed in the target cell population 12, 13 or by polyethylene glycol treatment of virus particles.
14 These two-component approaches suffer from potential instability as well as having a limited use in retargeting replication-competent adenoviruses. Retargeting strategies by modification of the viral genome include deleting the binding sites for CAR and a v b 3 /a v b 5 integrins and inserting short peptide ligands with specificity for target cells. [15] [16] [17] [18] [19] These approaches have produced somewhat conflicting results with regard to liver transduction. Some papers have reported significant reduction in liver transduction using vectors deleted for both CAR and integrin binding sites, while others demonstrate that similar deletions have no effect in detargeting the liver. These discrepancies have been suggested to be caused by the differences in the type of the deletion mutation as well as in the route of administration of the virus. Another approach is to use adenoviruses with hybrid serotypes by swapping the fiber gene from one serotype to another. There are at least 51 serotypes of human adenoviruses, which are divided into six subgroups (A-F). Native viruses in different subgroups have different tissue tropisms and it has been demonstrated that at least viruses in subgroup B, which includes serotype 35, do not use CAR as a physiologically relevant receptor and the receptor for most subgroup B adenoviruses was recently discovered to be CD46, a complement regulatory protein with multiple isoforms. [20] [21] [22] This suggests that fiber-swapping can be utilized to redirect adenovirus tropism and the feasibility of this approach has been successfully demonstrated for several hybrid serotypes including Ad5/3, Ad5/7, Ad5/16, Ad5/35 and Ad2/17. Using this strategy, hybrid adenoviruses have shown favorable tropism profiles for several cell types, including ovarian and breast cancer cells, hematopoetic stem cells, dendritic cells, HUVECs, smooth muscle cells and neurons. 11, [23] [24] [25] [26] [27] [28] In an attempt to develop a specific gene delivery system for the tumor endothelium, we have analyzed the ability of the recently developed Ad5/35 hybrid virus to transduce endothelial cells in vitro as well as in a rat hepatocellular carcinoma (HCC) model.
Results

Characterization of target cells
The goal of this paper was to analyze the transduction efficiency of the recently described Ad5/35 vector to endothelial cells. In the Ad5/35 system, the fiber shaft and knob domains of the standard adenovirus serotype 5 have been replaced by the shaft and knob domains of serotype 35. This hybrid virus binds to a cellular receptor, which was recently identified as CD46, resulting in a different tropism as compared with Ad5. 20 In order to compare endothelial cell transduction of Ad5/35 with Ad5 in vitro, human HUVECs and human aortic endothelial cells (HAECs) as well as three liver cell lines (Hep3B, HepG2 and BRL) were chosen. Flow cytometry was used to determine the expression levels of CD46, CAR and a v integrins for the human cell lines used in the study (Figure 1 ). FACS analyses demonstrated that Hep3B and HepG2 liver cells express high levels of all three adenovirus receptors. In contrast, HUVECs and HAECs expressed high levels of CD46 and a v integrins, but had very low CAR expression on their cell surface, suggesting that viral transduction through CD46, but not CAR, would result in efficient transduction to endothelial cells.
In vitro transduction of Ad5 and Ad5/35
In order to analyze the transduction efficiency of Ad5/35 to endothelial cells, a series of in vitro transduction assays was performed (Figure 2 ). We chose several liver cell lines as controls in these experiments, since it has previously been demonstrated that after systemic administration, the majority of a nontargeted adenovirus will be taken up by liver, potentially causing significant toxicity. 29 HUVECs Moreover, the larger size of the rat as compared with the mouse permitted virus administration via the hepatic artery, which is routinely used to administer chemotherapeutic agents to HCC patients in the clinic. Syngeneic McA-RH777 HCC cells were implanted directly into the left lateral lobe of the liver. After 14 days, when tumors reached 13-18 mm in diameter, Ad5.LacZ or Ad5/ 35.LacZ was injected via the hepatic artery. Initially, the maximal tolerable dose (MTD) was determined for both viruses in this model. Animal survival was assessed after administration of increasing doses of both viruses and MTD was defined as the highest dose which did not kill any animals in the group. Based on this experiment, the MTD doses were 1.2 Â 10 12 vp for Ad5/35.LacZ and 1.2 Â 10 11 vp for Ad5.LacZ (data not shown). However, for direct comparison of the differences in viral tropism, the same dose was used for both viruses.
In order to assess the differences in viral tropism in the HCC model, 1.2 Â 10 11 vp of Ad5.LacZ and Ad5/35.LacZ were administered to three tumor-bearing rats for both groups via the hepatic artery. After 72 h, the animals were killed and analyzed for viral transgene expression. In the rats infused with Ad5.LacZ, b-galactosidase expression was detected primarily in the liver parenchyma, whereas only few tumor cells exhibited b-galactosidase-positive staining (Figure 3) . The positive cells in the liver parenchyma were diffusely scattered in the tissue, with no clear preference for the endothelial cells in the liver. In Ad5/35.LacZ-infused rats, the staining pattern was clearly different. The majority of positive cells were detected in the tumor rim, where most of the Figure  3 ). These results demonstrate that Ad5/35 has a clearly different tropism from Ad5 in vivo and suggest that this virus could be used to deliver genes to sites of neoangiogenesis in liver tumors. In order to further characterize the cellular localization of Ad5/35.LacZ in vivo, double staining using monoclonal antibodies for CD46 as well as known endothelial cell markers CD31 and Flk-1 was employed (Figure 4) . Examination of the double-stained sections at high magnification ( Â 100) revealed colocalization of viral b-galactosidase with either CD31 or Flk-1 stained cells, indicating that Ad5/35 is able to transduce endothelial cells in vivo. In addition, double stainings for viral b-galactosidase and CD46 revealed that Ad5/35.LacZ is either colocalized or in close proximity of CD46-positive cells, suggesting that CD46 acts as a receptor for Ad5/35 in our in vivo model.
Discussion
Angiogenesis has been recognized as a critical step in tumor progression and metastasis and a number of approaches have been undertaken to interfere with the angiogenic process to prevent tumor growth. Direct targeting of the dividing endothelial cells in growing tumors offers the advantage of aiming at a genetically stable cell population that is easily accessible through the bloodstream. The feasibility of this approach was initially established by using a bispecific antibody to target human tissue factor to tumor endothelial cells. The tissue factor-antibody complex caused thrombosis in the tumor vasculature resulting in tumor Endothelial targeting by a hybrid virus K Shinozaki et al regression. 30 Subsequently, similar approaches have been employed to target cytotoxic or antiangiogenic proteins to tumor vasculature, including targeting tumor necrosis factor alpha and interleukin-12 to ED-B domain of fibronectin. 31, 32 In addition, chemotherapeutic agents and proapoptotic peptides have been directed to tumor endothelium using short targeting peptides. 33, 34 The specificity of direct targeting can be further enhanced by using vectors capable of gene delivery, where therapeutic genes can be placed also under transcriptional control. In addition, this approach enables the combination of multiple therapeutic genes in a single vector and the use of replication-competent viruses, a promising new approach in cancer gene therapy. 35 Previously, cationic nanoparticles as well as bone marrow-derived, endothelial progenitor-like cells have been successfully used to deliver therapeutic genes to tumor endothelium. 2, 3 In addition, a retrovirus harboring a matrix-targeting motif as well as a transcriptionally targeted lentivirus have been shown to selectively target angiogenic regions within tumor nodules. 36, 37 Adenoviruses are currently the most widely used vectors for cancer gene therapy, and despite several successful approaches of targeting adenoviruses to endothelial cells in vitro, the in vivo targeting of adenoviruses to tumor vessels has been difficult to achieve. 12, 13, 15 In this report, we explore the feasibility of targeting adenoviral vectors to tumor endothelial cells using fiber serotype replacement. The fiber replacement strategy has previously been used with several other serotypes including 3, 7 and 17. 22, 24, 26, 28 These fiber replacements have enabled virus retargeting to, for example, ovarian cancer, central nervous system and airway epithelium. The Ad5/35 hybrid virus has previously been used to target hematopoetic stem cells, dendritic cells and certain breast cancer cells. 11, 23, 25 A detailed biodistribution study demonstrated an effective uptake by liver nonparenchymal cells after intravenous administration of Ad5/35. 38 Here we describe a potential new application for this vector.
In vitro infection assays demonstrated the superiority of Ad5/35 hybrid vector in infecting endothelial cells as compared to the standard Ad5 vector. At MOI 120 Ad5/ 35 transduced 100% of HUVECs whereas infection with Ad5 resulted in transduction of 10% of the cells ( Figure  2b) . The difference between the two viruses was even more striking in HAECs, where Ad5/35 infection with only MOI 3.6 was sufficient to transduce 95% of cells. In order to achieve comparable transduction with Ad5, HAECs had to be infected with MOI 1200. Quantification of the lacZ reporter gene expression revealed an over 10-fold increase in gene expression from Ad5/35 in HUVECs as compared with Ad5 (Figure 2c ). For HAECs, this difference was even clearer. In contrast, liver cells were far more transducable by Ad5 than Ad5/35. The situation was most pronounced in BRL rat liver cells, where reporter gene expression was increased over 50-fold in Ad5-infected cells. In human liver cells the difference was less clear, but infection with Ad5 still resulted in more than two-fold reporter gene expression than Ad5/35. These results are comparable in terms of the increase in endothelial infectivity to earlier reports 
Endothelial targeting by a hybrid virus
K Shinozaki et al were Ad5 infectivity was enhanced by adding targeting motifs to the HI loop of the fiber knob without abolishing CAR binding. 39 The marked difference between liver cells from different species is probably a reflection of the different expression profile of CD46 in rat and human. 40 Nevertheless, when comparing endothelial and liver cells of human origin, the Ad5/35 vector achieves a therapeutic ratio of at least over 20 and it is notable that therapeutic ratios of many conventional cytotoxic drugs range from 1.5:1 to 6:1. 41 To determine the transduction efficiency of Ad5/35 in vivo, we used a rat hepatoma model. The larger size of rat vasculature as compared to mouse enabled us to administer the vectors via the hepatic artery, a route that is routinely used in the clinic to deliver cytotoxic compounds. Injection of Ad5 to the hepatic artery resulted in b-galactosidase expression mainly in the liver parenchyma, whereas only few tumor cells were b-galactosidase-positive (Figure 3) . In contrast, Ad5/35-infused rats demonstrated b-galactosidase expression mainly in the periphery of the tumor with little reporter gene expression in the normal liver parenchyma. As the tumor periphery has been previously shown to contain the so-called angiogenic rim where most active neovasculature formation is taking place, this expression pattern suggested that Ad5/35 was able to transduce endothelial cells in the tumors. 42 Double stainings using known endothelial cell markers confirmed the localization of viral b-galactosidase to endothelial cells ( Figure  4) . In a previous in vivo study using a mouse breast carcinoma metastasis model, Ad5/35 failed to efficiently transduce breast carcinoma metastases in the liver after tail vein administration of the virus. 11 This dissimilarity may be due to the different rodent model as well as the tumor type. In addition, the route of virus administration (intrahepatic artery vs tail vein) is likely to play a significant role in viral tropism.
CD46 has been recently discovered to be a receptor for most group B adenoviruses, including Ad35. 20 As CD46 is expressed in most human tissues, the Ad5/35 vector can infect other cell types besides endothelial cells. However, as CD46 has many isoforms that have tissuespecific expression, it is not currently known whether all isoforms can mediate Ad35 transdcuction with equal efficiency and our results suggest that liver cells are less susceptible to Ad5/35 infection than endothelial cells despite similar CD46 expression profiles. In addition, Ad5/35 transduced HAECs far more efficiently than HUVECs even though both cell types express high levels of CD46. This suggests that additional viral receptors or cell type-specific factors may influence Ad5/35 transduction. Many cell types, including endothelial cells, express heparan sulfates, which have been shown to be able to act as secondary adenoviral attachment receptors and can thus influence adenoviral tropism. 43 Furthermore, the a v b 3 /a v b 5 integrins that are required for internalization of the hybrid virus are highly overexpressed in tumor endothelial cells and a cationic nanoparticle coupled to an integrin a v b 3 -targeting ligand was recently used to deliver genes selectively to angiogenic blood vessels. 2 The selectivity of Ad5/35 targeting can also be markedly improved by locoregional administration as demonstrated here by using hepatic artery delivery.
In summary, we demonstrate here that replacing the fiber molecule on the standard serotype 5 adenovirus with the serotype 35 fiber results in a marked improvement on transduction efficiency to endothelial cells in vitro as well as in vivo. This vector may be used as a powerful tool to deliver therapeutic genes to tumor vasculature.
Materials and methods
Cells and viruses
Hep3B, HepG2, BRL and McA-RH7777 cell lines were obtained from American Type Culture Collection. HAECs were obtained from Clonetics Corporation (Wakersville, MD, USA). HUVECs were isolated from umbilical cords (Institutional Review Board-approved cord blood program) by collagenase type IV (SigmaAldrich Inc., St Louis, MO, USA) perfusion (0.2% in Hanks' balanced salt solution) for 20 min at room temperature. Hep3B, HepG2, BRL and McA-RH7777 cells were cultured in DMEM medium supplemented with 10% FBS, 0.2 mM glutamine, and penicillin/streptomycin. In addition, Hep3B medium was supplemented with 1 mM sodium pyruvate. HAECs and HUVECs were cultured in EGM-2 medium (Clonetics).
Recombinant adenoviruses Ad5.LacZ and Ad5/ 35.LacZ were prepared by cotransfecting 293 cells with E1-deleted shuttle plasmid pAd.RSV.LacZ with backbone plasmids pBHG10 (for Ad5.LacZ), or pAdDCF35 as described. 44 pAdDCF35 is based on pBHG10 (Microbix Biosystems Inc., Toronto, Canada), where the Ad5 fiber gene was replaced with the Ad35 fiber gene, as previously described. 25 Viruses were isolated from a single plaque, expanded in 293 cells and purified by double cesium gradient ultracentrifugation. The viral particles were measured by optical absorbance at 260 nm, and the plaque-forming units (PFU) were determined by standard agarose-overlay plaque assay on 293 cells. The E1-deleted b-gal virus was produced by cotransfecting pCMV-lacZ shuttle plasmid with pBHG10 backbone plasmid as described above.
Virus infections and reporter gene analysis
Â 10
4 cells/well were plated on 24-well dishes 24 h before infection. Cells were infected with indicated MOIs of virus in 300 ml serum-free medium. After a 2-h incubation at 371C, cells were washed once with prewarmed PBS and 500 ml complete medium was added to each well. For in situ staining of cells for b-galactosidase activity, after an additional 48 h the cells were washed twice with PBS, fixed with 0.25% glutaraldehyde in PBS and incubated in X-Gal solution (Promega, Madison, WI, USA) for 3 h at 371C. The cells were then washed once with PBS, photographed and the percentage of b-galactosidase positive cells were counted independently by two investigators.
For quantitative measurement of b-galactosidase activity, the b-galactosidase enzyme assay system (Promega) was used. Briefly, after 48-h incubation the cells were lysed using reporter lysis buffer and the enzyme activity was measured using assay buffer according to the instructions provided by the supplier. Protein content in each sample was measured using Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA, USA) and the enzyme activity was correlated for the total protein content in each sample. 11 vp for Ad5.LacZ. However, for direct comparison of the differences in viral tropism, the same dose (1.2 Â 10 11 vp) was used for both viruses. Viruses were injected to the rats 14 days after tumor cell implantation. To assess virus spread in the tumor and in the liver, animals were euthanized at 72 h after vector injection and livers were removed for analysis. Representative results are shown in the figures.
For histological examination, immunohistochemistry and b-galactosidase expression analysis, the harvested livers were fixed in 1% paraformaldehyde for 4 h, and then in 18% sucrose solution overnight. After fixation, the blocks were embedded in Tissue-Tek (Sakura Finetek USA, Torrance, CA, USA). Cryostat sections of 10 mm thickness were stained by immersion in X-Gal (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside) staining solution for 16 h at 371C. Sections were counterstained with nuclear fast red (Vector Laboratories, Burlingame, CA, USA). Immunohistochemistry was performed using monoclonal antibodies for known endothelial markers CD31 (BD Biosciences) and Flk-1 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) as well as for CD46 (Santa Cruz Biotechnology Inc.). For double stainings, sections were first incubated with a monoclonal antibody, rinsed twice in PBS, and stained for b-gal. In situ detection of b-galactosidase activity in the sections was performed using X-gal as suggested by the supplier (Promega).
